NOVOCURE LTD's ticker is NVCR and the CUSIP is G6674U108. A total of 312 filers reported holding NOVOCURE LTD in Q4 2021. The put-call ratio across all filers is 0.86 and the average weighting 0.1%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q3 2023 | $1,023,280 | -88.6% | 63,361 | -70.7% | 0.00% | -88.9% |
| Q2 2023 | $8,988,984 | +829.2% | 216,602 | +1246.5% | 0.02% | +800.0% |
| Q1 2023 | $967,412 | -86.7% | 16,086 | -84.6% | 0.00% | -86.7% |
| Q2 2022 | $7,282,000 | +2617.2% | 104,760 | +2832.8% | 0.02% | – |
| Q4 2021 | $268,000 | -47.6% | 3,572 | +21.0% | 0.00% | -100.0% |
| Q4 2020 | $511,000 | +41.9% | 2,951 | -82.1% | 0.00% | -80.0% |
| Q1 2018 | $360,000 | – | 16,500 | – | 0.02% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Nordwand Advisors, LLC | 1,515,000 | $111,125,249 | 13.86% |
| Invus Financial Advisors, LLC | 350,884 | $25,737,341 | 13.70% |
| HARTLINE INVESTMENT CORP/ | 304,482 | $22,333,755 | 5.08% |
| GREAT POINT PARTNERS LLC | 241,000 | $17,677,350 | 3.46% |
| Tri Locum Partners LP | 72,400 | $5,311,000 | 2.15% |
| Taylor Frigon Capital Management LLC | 42,061 | $3,085,174 | 1.75% |
| HighVista Strategies LLC | 28,007 | $2,054,313 | 1.22% |
| HAP Trading, LLC | 124,500 | $10,294 | 1.05% |
| Private Harbour Investment Management & Counsel, LLC | 12,285 | $901,105 | 0.99% |
| INTERNATIONAL BIOTECHNOLOGY TRUST PLC | 32,000 | $2,344,000 | 0.72% |